Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin

Dunphy, Frank; Dunleavy, Teresa L.; Harrison, Bruce R.; Boyd, James H.; Varvares, Mark A.; Dunphy, Cherie H.; Rodriguez, Jack J.; McDonough, Erin; Minster, Jeffrey R.; McGrady, Murray D.

doi:10.1002/(sici)1097-0142(19970415)79:8<1623::aid-cncr28>3.3.co;2-p

Cited by 3 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results further support those of other clinical studies that have documented the efficacy of epoetin alfa in increasing Hb levels and reducing transfusion requirements in anaemic patients with non-myeloid malignancies, including multiple myeloma (Abels, 1993;Ludwig et al, 1993Ludwig et al, , 1995Dunphy et al, 1997;Glaspy et al, 1997;Demetri et al, 1998). Several studies were conducted specifically in multiple myeloma patients who had received or were receiving chemotherapy for advanced or longstanding disease and had severe anaemia.…”

Section: Discussionsupporting

confidence: 85%

“…A glycoprotein hormone, epoetin alfa increases the production of RBCs by stimulating the expansion of erythroid progenitor cells and decreasing apoptosis of erythroid burst-forming unit cells and granulocyte colony-forming unit cells (San Miguel et al, 1999). Clinical studies have demonstrated that epoetin alfa can prevent or ameliorate anaemia and reduce transfusion requirements in anaemic patients with a variety of cancers, including multiple myeloma (Ludwig et al, 1990(Ludwig et al, , 1993Abels, 1992;Barlogie & Beck, 1993;Leitgeb et al, 1994;Dunphy et al, 1997;Mittelman et al, 1997;Musto et al, 1997;Dammacco et al, 1998). Furthermore, several studies with a combined total of nearly 5000 evaluable patients have shown that correction of anaemia with epoetin alfa can improve the QOL in patients with cancer (Ludwig et al, 1990;Abels, 1992;Leitgeb et al, 1994;Glaspy et al, 1997;Mittelman et al, 1997;Demetri et al, 1998).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

2001

View full text Add to dashboard Cite

Summary. Effects of epoetin alfa on transfusions, haemoglobin (Hb) and quality of life (QOL) were evaluated in a placebo-controlled study of 145 patients with multiple myeloma and anaemia (Hb , 11 g/dl). During the 12-week, double-blind phase, patients received 150 IU/kg epoetin alfa or a matching volume of placebo subcutaneously three times weekly; the dose (or volume) was doubled at week 4 if Hb response was inadequate. Patients completing this phase could enter the subsequent optional 12-week phase of open-label epoetin alfa treatment. During double-blind treatment, epoetin alfa significantly decreased the incidence of transfusion compared with placebo (28% vs. 47%, P 0´017), regardless of patients' transfusion history, and increased mean Hb (1´8 g/dl vs. 0´0 g/dl, P , 0´001). Univariate analysis showed significant (P # 0´05) improvement in more QOL measures with epoetin alfa than with placebo; multivariate analysis discerned no between-treatment differences. Significantly (P 0´038) more epoetin alfa vs. placebo patients had improved performance scores. At the end of the open-label treatment phase, patients who had continued epoetin alfa maintained Hb status, and placebo patients who were switched to epoetin alfa had mean Hb increases of 2´4 g/dl. Adverse events were similar between treatment groups. Epoetin alfa proved effective and well tolerated for treating anaemia in patients with multiple myeloma.

show abstract

Section: Discussionsupporting

confidence: 85%

mentioning

confidence: 99%

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

2001

View full text Add to dashboard Cite

show abstract

“…Additional trials emphasize the wide variation of eligibility criteria for serum creatinine used: 1.5 mg/100 mL; 21 Յ1.8 mg/100 mL; 52 Ͻ2 mg/100 mL; 52-55 and 3 mg/100 mL. 27 In the multicenter study of Glaspy et al 51 with 2342 enrolled patients, the renal state of the patients was not covered at all. In several publications only vague phrases such as "normal renal parameters" 19,22,25,46 are noted.…”

Section: Renal Entry Criteria In Previous Rhepo Trialsmentioning

confidence: 99%

Response and prediction of response to recombinant human erythropoietin in patients with solid tumors and platinum-associated anemia

Fjornes

1999

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective. Anemia is commonly observed in tumor patients and may be worsened by the concomitant administration of chemotherapy with platinum. Recombinant human erythropoietin (rhEPO) is able to improve the chemotherapy-associated anemia and the quality of life in patients with solid tumors. The most effective dose, route, and frequency of administration of rhEPO in anemic cancer patients has not yet been determined.The purpose of this review is to describe the results obtained up to now concerning the response and prediction of response to rhEPO in anemic patients with solid tumors undergoing platinum-based chemotherapy. In particular, the renal function conditions in this patient group were examined. Data sources. The literature was reviewed through a MEDLINE search covering 1987 to 1997. Relevant articles were additionally obtained by the systematic examination of article references. We searched the following terms: rhEPO, tumor, anemia, cisplatin, carboplatin, and renal failure.Study Selection. The current literature was reviewed with regard to both the pathophysiology of platinum-induced anemia and the clinical use, indications, and dosage of rhEPO in anemic tumor patients undergoing platinum therapy. Particular attention was directed to the prediction criteria of this drug.Conclusions. The rhEPO response rates in patients with solid tumors and platinum-associated anemia vary widely in the current literature and range from 36% to 82%. Unfortunately, no strong predictor of response can be recommended at the present time. Clinical studies support findings concerning a reduction in renal function parameters and a blunted erythropoietin response in patients with platinuminduced anemia. It is possible that a baseline serum erythropoietin concentration in conjunction with the serum creatinine concentration or the creatinine clearance value can serve as a prognostic indicator for rhEPO therapy response in this patient group.

show abstract

The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients

Heras¹,

Papapetropoulos²,

Karagiannis

et al. 2005

Eur J Cancer Care

View full text Add to dashboard Cite

The aim of this study was to evaluate the effectiveness and the impact of once-weekly administration of epoetin alfa (Ea) on the management of anaemia and on the quality of life (QOL) of cancer patients receiving chemotherapy. Eighty cancer patients with life expectancy > or = 24 weeks and haemoglobin (Hb) levels < 10.5 g/dL were studied. After an initial screening of patients' demographic and clinical characteristics, Ea 40000 U once a week was administered over a period of 4 months. In case of patients with Hb level exceeding > 14 g/dL or in case of non-response, the dosage was reconsidered. Every month, data regarding Hb levels, clinical variations, changes in the chemotherapy regimen and transfusion use since the last study visit, were evaluated. The Linear Analogue Scale Assessment scale was used for the evaluation of the QOL. The readmissions to hospital rates (P < 0.002) and the transfusion use rates (P < 0.003) were significantly decreased comparatively with baseline. A mean increase from baseline to the final Hb level (P < 0.001) was established, as well as a significant improvement in the functional ability, energy and in the overall QOL (P < 0.001). In conclusion, the treatment of cancer patients with Ea once-weekly is effective and safe, improving their haematological parameters and QOL.

show abstract

Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin

Cited by 3 publications

References 1 publication

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

Response and prediction of response to recombinant human erythropoietin in patients with solid tumors and platinum-associated anemia

The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients

Contact Info

Product

Resources

About